TRC Autologous Bone Marrow Cells for the Treatment of Appendicular Skeletal Fracture Non-Union

Trial Profile

TRC Autologous Bone Marrow Cells for the Treatment of Appendicular Skeletal Fracture Non-Union

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Ixmyelocel-T (Primary)
  • Indications Fracture
  • Focus Therapeutic Use
  • Sponsors Vericel Corporation
  • Most Recent Events

    • 08 Mar 2017 Status changed from completed to discontinued for business reasons (not safety reasons).
    • 02 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top